Customisable 3D human Bioprinted Platforms

• Proprietary technology platform

• Adaptable 3D humanized bioprinting technology

  • For discovery of novel products

  • For development of products and product concepts

  • To generate POC to support product development

  • Features:

    • Simulates in vivo behavior of products. Mimics human physiology due to multiple cell types connected

    • Predicts success and failure points in product development, optimize clinical trial design and optimization

    • Predicts potential toxicological pitfalls

    • Rapid and affordable

    • Allows for and support better design to bridge the gaps between animal studies and human studies

• 3D Cell models utilise multiple cell types to mimic human physiology where multiple cells interact for a multi step pharmacology or toxicology outcomes.

  • Can be considered equivalent to human organs with overlaying multiple cell types

  • Successfully developed 3D Human vascular lung model and applied for

  • Sepsis – Collaboration with ISSAR PHARMA

    • Screened several targeted peptides for efficacy evaluation

  • Covid Drug Repurposing – Collaboration with Indra’s and Tech Mahindra

    • Screened several FDA approved drugs to repurpose for covid prevention and treatment

Polyclonal IgY antibody technology against disease targets

• IgY antibodies raised in chickens are used for passive immunotherapy.

• ImmunIgY for COVID-19 contains antibodies against the Receptor Binding Domain (RBD) of spike protein of SARS-CoV-2 virus. These antibodies neutralize both original Wuhan strain as well as Delta strain (www.myimmunigy.com).

• Multiple products for intangible targets are in development